ReviewJournal of chest surgery2026
Organoids in Cancer Research: Current Applications, Limitations, and Technological Advances.
Review in Journal of chest surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Current Perspectives on 2D and 3D Cell Culture Models in Cancer Research: Molecular Determinants of Tumor Biology and Therapeutic Response.Current issues in molecular biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Organoids are 3-dimensional cell culture systems derived from stem cells through self-organization. They recapitulate key aspects of tissue architecture and organ-specific functions, providing a powerful preclinical platform for cancer research. In particular, patient-derived tumor organoids preserve the pathological and genetic features of primary tumors. These models support the prediction of patient-specific drug responses and thereby advance precision medicine. Despite these advantages, several challenges remain, including incomplete reconstruction of the tumor microenvironment-particularly immune components- and insufficient vascularization. Recent advances have sought to address these limitations through innovative approaches, including immune cell co-culture systems and organoid-on-a-chip technologies. This mini-review summarizes recent progress in tumor organoid research and highlights emerging strategies aimed at improving physiological relevance. It also discusses future perspectives, emphasizing the expanding roles of organoids in precision oncology and regenerative medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.